As of 2026-03-21, the Relative Valuation of Neogenomics Inc (NEO) is (20.16) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.96 USD, the upside of Neogenomics Inc based on Relative Valuation is -353.3%.
The range of the Relative Valuation is (21.25) - (19.51) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 25.5x - 30.2x | 27.4x |
| Forward P/E multiples | 19.4x - 23.4x | 21.0x |
| Fair Price | (21.25) - (19.51) | (20.16) |
| Upside | -367.0% - -345.1% | -353.3% |
| Date | P/E |
| 2026-03-16 | -9.90 |
| 2026-03-13 | -9.47 |
| 2026-03-12 | -9.59 |
| 2026-03-11 | -10.27 |
| 2026-03-10 | -10.29 |
| 2026-03-09 | -10.72 |
| 2026-03-06 | -10.77 |
| 2026-03-05 | -10.97 |
| 2026-03-04 | -10.94 |
| 2026-03-03 | -11.46 |
| 2026-03-02 | -11.42 |
| 2026-02-27 | -11.81 |
| 2026-02-26 | -12.22 |
| 2026-02-25 | -11.80 |
| 2026-02-24 | -11.60 |
| 2026-02-23 | -11.98 |
| 2026-02-20 | -11.88 |
| 2026-02-19 | -12.03 |
| 2026-02-18 | -12.33 |
| 2026-02-17 | -13.75 |
| 2026-02-13 | -13.67 |
| 2026-02-12 | -13.42 |
| 2026-02-11 | -13.76 |
| 2026-02-10 | -13.82 |
| 2026-02-09 | -13.64 |
| 2026-02-06 | -13.72 |
| 2026-02-05 | -13.54 |
| 2026-02-04 | -14.38 |
| 2026-02-03 | -15.02 |
| 2026-02-02 | -14.79 |
| 2026-01-30 | -14.49 |
| 2026-01-29 | -14.90 |
| 2026-01-28 | -14.88 |
| 2026-01-27 | -14.98 |
| 2026-01-26 | -14.94 |
| 2026-01-23 | -15.39 |
| 2026-01-22 | -15.59 |
| 2026-01-21 | -15.25 |
| 2026-01-20 | -15.19 |
| 2026-01-16 | -15.37 |
| 2026-01-15 | -15.42 |
| 2026-01-14 | -15.89 |
| 2026-01-13 | -15.54 |
| 2026-01-12 | -15.01 |
| 2026-01-09 | -15.81 |
| 2026-01-08 | -15.42 |
| 2026-01-07 | -15.23 |
| 2026-01-06 | -15.38 |
| 2026-01-05 | -14.52 |
| 2026-01-02 | -14.13 |